Characteristic | n = 41 localized tumors |
---|---|
Quality of surgery | |
Resection | |
R0 | 22 (53%) |
R1 | 13 (32%) |
R2 | 4 (10%) |
Tumor rupture | |
Yes | 9 (22%) |
No | 29 (70%) |
Primary surgery/Post imatinib surgery | 29/12 |
Post-operative complications | 7 (17%) |
Anastomotic leakage of coloanal anastomosis | 2 |
Small bowel fistula with death | 1 |
Pelvic peritonitis | 1 |
Pararectal abscess and anorectal fistula | 1 |
Occlusion | 1 |
Fever | 1 |
Imatinib (IM) therapy group (400 mg/day) | 16 (37.5%) |
Preoperative IM | 12 (30%) |
No neoadjuvant IM group (immediate surgery) | 29 (70%) |
Post operative IM | 11 (27%) |
from « neoadjuvant group » | 7 |
from « immediate surgery group » | 4 |
Median duration preoperative IM (month) | 7 (2-12) |
Median duration post operative IM (month) | 7 (2-41) |
Efficacy of preoperative IM therapy | 12 |
Partial response | 8 |
Complete response | 1 |
Stable disease/minor response | 3 |